SCHEMBL21949044

SCHEMBL21949044

O=C(O)c1cnc(Cl)cc1NC1CCCC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 3/20 0.52
CA2 P00918 3/20 0.52
CA3 P07451 3/20 0.52
CA6 P23280 3/20 0.52
CA7 P43166 3/20 0.52
CA5B Q9Y2D0 3/20 0.52
CA12 O43570 2/20 0.52
CA9 Q16790 2/20 0.52
CA13 Q8N1Q1 2/20 0.52
CISD1 Q9NZ45 1/20 0.52
CA4 P22748 1/20 0.52
CA14 Q9ULX7 1/20 0.52
KMT2A Q03164 3/20 0.49
MEN1 O00255 2/20 0.49
ALDH1A1 P00352 1/20 0.49
HCAR3 P49019 5/20 0.46
MAPK8 P45983 1/20 0.40
KMT5B Q4FZB7 2/20 0.40
KMT5C Q86Y97 2/20 0.40
KDM4E B2RXH2 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30883513 1.00 CA1 (0.52) CA1CA2CA3CA6CA7
SCHEMBL21949096 0.99 CA1 (0.54) CA1CA2CA3CA6CA7
SCHEMBL31436651 0.94 CA1 (0.45) CA1CA2CA3CA6CA7
SCHEMBL4404049 0.94 CA1 (0.45) CA1CA2CA3CA6CA7
SCHEMBL23335415 0.88 CISD1 (0.43) CA1CA2CA3CA6CA7
SCHEMBL23335401 0.88 CISD1 (0.43) CA1CA2CA3CA6CA7
SCHEMBL15714950 0.88 MAPK8 (0.46) CA1CA2CA3CA6CA7
SCHEMBL15688645 0.88 MAPK8 (0.46) CA1CA2CA3CA6CA7
SCHEMBL15688807 0.88 MAPK8 (0.46) CA1CA2CA3CA6CA7
SCHEMBL23335583 0.87 MELK (0.41) CA1CA2CA3CA6CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4572755-A2 CDK2 DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2025-06-25 EP disclosed
US-20240173419-A1 CDK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2024-05-30 US disclosed
WO-2024039901-A2 CDK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2024-02-22 WO disclosed
EP-3089973-B1 HETEROARYL SUBSTITUTED NICOTINAMIDE COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2020-04-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240173419-A1 CDK2 DEGRADERS AND USES THEREOF CDK2, CDK20, CDK1 CA1 2858/4885CA2 3399/4885CA3 2272/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.